Drugs / Hodgkin's antigens-GM-CSF-expressing cell vaccine
Hodgkin's antigens-GM-CSF-expressing cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00478062 | Apr 2007 → Jun 2008 | lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hodgkin's antigens-GM-CSF-expressing cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00478062 ↗ |
| Modality | Vaccine | “Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells.” NCT00478062 ↗ |